USFDA gives approval for Plerixafor injection

The product is being launched this month, Aurobindo Pharma said.

66
USFDA Approval
USFDA Approval

Last Updated on October 11, 2024 by The Health Master

New Delhi: Aurobindo Pharma Ltd said its wholly-owned arm Eugia Pharma Specialities has received a final approval from the US health regulator for its generic version of Plerixafor injection indicated for patients with certain types of cancer to prepare them for stem cell transplant.

The approval granted by the US Food & Drug Administration (USFDA) is to manufacture and market Plerixafor Injection of strengths 24 mg/1.2 mL (20 mg/mL), single-dose vial, Aurobindo Pharma said in a regulatory filing.

It is bioequivalent and therapeutically equivalent to the reference listed drug, Mozobil injection, 24 mg/1.2 mL (20 mg/mL) of Genzyme Corporation.

Advt Plerixafor injection is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilise hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma (NHL) or multiple myeloma (MM), the company said.

The product is being launched this month, Aurobindo Pharma said.

The approved product has an estimated market size of around USD 210 million for the 12 months ending May 2023, it said citing IQVIA data.

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news